Corinne Maurice‐Dror

First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆

Jiaxin Niu, Corinne Maurice‐Dror, D.H. Lee et al. · Annals of Oncology · 2021 · 287 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer

Nicolette M. Fonseca, Corinne Maurice‐Dror, Cameron Herberts et al. · Nature Communications · 2024 · 120 citations · Full text

Medicine, Biostatistics, Oncology +17

Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors

Alexander Muik, Elena Garralda, Friederike Gieseke et al. · Cancer Discovery · 2022 · 113 citations · Full text

Life Sciences, Immunology, Oncology +17

A phase I study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36γ, for intratumoral (iTu) injection alone and in combination with durvalumab.

Manish R. Patel, Todd M. Bauer, Antonio Jimeno et al. · Journal of Clinical Oncology · 2020 · 69 citations

Medicine, Oncology, Pharmacology +16

Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase II LEAP-005 study.

Luis J. Villanueva-Rivera, Zarnie Lwin, Hyun Cheol Chung et al. · Journal of Clinical Oncology · 2021 · 69 citations

Medicine, Oncology, Pharmacology +15